Synthesis and activity of novel 1- or 3-(3-amino-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones as selective norepinephrine reuptake inhibitors (original) (raw)

A series of novel 1- or 3-(3-amino-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones were synthesized and evaluated for their activity as selective norepinephrine reuptake inhibitors (NRIs). Compounds 15 and 20 demonstrated significant hNET potency and selectivity compared to existing NRIs such as reboxetine and atomoxetine. Given the importance of norepinephrine in treating neurological disorders, these new compounds may represent valuable advancements in the development of effective therapeutic agents.